Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis

Authors: Lijuan Chen, Hua Tian, Meng Li, Chao Ge, Fangyu Zhao, Lixing Zhang, Hong Li, Junxi Liu, Tingpu Wang, Ming Yao, Jinjun Li

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

We have previously demonstrated that isocorydine (ICD) can be served as a potential antitumor agent in hepatocellular carcinoma (HCC). A novel derivate of isocorydine (d-ICD) could significantly improve its anticancer activity in tumors. However, the molecular mechanisms of d-ICD on HCC cells remain to be unclear. In this study, we observed that d-ICD inhibited cell proliferation and induced apoptosis of HCC cells in a concentration-dependent manner. We found d-ICD induced G2/M cycle arrest of HCC cells via DNA damage 45 alpha (GADD45A) and p21 pathway in vitro and in vivo. In d-ICD-treated cells, cell cycle-related proteins cyclin B1 and p-CDC2 were upregulated and p-cyclin B1, CDC2, and E2F1 were inhibited. p21 expression can be reversed by knockdown of GADD45A in d-ICD-treated HCC cells. Enforced expression of CCAAT/enhancer-binding protein β (C/EBPβ) in combination with d-ICD enhanced the p21 expression in HCC cells. Furthermore, the luciferase reporter assay showed that upregulation of GADD45A by C/EBPβ was achieved through the increase of GADD45A promoter activity. These findings indicate that d-ICD inhibits cell proliferation and induces cell cycle arrest through activation of C/EBPβ-GADD45A-p21 pathway in HCC cells. d-ICD might be a promising chemotherapeutic agent for the treatment of HCC.
Appendix
Available only for authorised users
Literature
1.
2.
Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–16.CrossRefPubMed
3.
Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007;8:149–60.CrossRefPubMed
4.
Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature. 2007;445:671–5.CrossRefPubMed
5.
Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, Sabour-Alaoui S, et al. April binding to bcma activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells. J Immunol. 2012;189:4748–58.
6.
Kim T, Cui R, Jeon YJ, Fadda P, Alder H, Croce CM. MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. Oncotarget. 2015;7:18780–9.
7.
Vera J, Raatz Y, Wolkenhauer O, Kottek T, Bhattacharya A, Simon JC, et al. Chk1 and Wee1 control genotoxic-stress induced G2-m arrest in melanoma cells. Cell Signal. 2015;27:951–60.CrossRefPubMed
8.
9.
Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S, et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14:1004–13.CrossRefPubMed
10.
Sun H, Hou H, Lu P, Zhang L, Zhao F, Ge C, et al. Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/m cell cycle arrest and apoptosis. PLoS One. 2012;7:e36808.CrossRefPubMedPubMedCentral
11.
Lu P, Sun H, Zhang L, Hou H, Zhang L, Zhao F, et al. Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Mol Med. 2012;18:1136–46.CrossRefPubMedPubMedCentral
12.
Zhong M, Liu Y, Liu J, Di D, Xu M, Yang Y, et al. Isocorydine derivatives and their anticancer activities. Molecules. 2014;19:12099–115.CrossRefPubMed
13.
Yan M, Li H, Zhao F, Zhang L, Ge C, Yao M, et al. Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissue. Chin J Cancer Res. 2013;25:289–98.PubMedPubMedCentral
14.
Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54:910–9.CrossRefPubMed
15.
Tian H, Ge C, Li H, Zhao F, Hou H, Chen T, et al. Ribonucleotide reductase m2b inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/akt1 pathway in hepatocellular carcinoma. Hepatology. 2014;59:1459–70.CrossRefPubMed
16.
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–8.CrossRefPubMed
17.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMed
18.
Liu K, Liu S, Zhang W, Ji B, Wang Y, Liu Y. Mir222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol. 2014;45:1537–46.PubMed
19.
Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, et al. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147–60.CrossRefPubMedPubMedCentral
20.
Sakaue-Sawano A, Kobayashi T, Ohtawa K, Miyawaki A. Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication. BMC Cell Biol. 2011;12:2.CrossRefPubMedPubMedCentral
21.
Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.CrossRefPubMed
22.
Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003;13:65–70.CrossRefPubMed
23.
Li D, Kang N, Ji J, Zhan Q. BRCA1 regulates transforming growth factor-beta (TGF-beta1) signaling through Gadd45a by enhancing the protein stability of Smad4. Mol Oncol. 2015;9:1655–66.
24.
Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMed
25.
Kearsey JM, Coates PJ, Prescott AR, Warbrick E, Hall PA. Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene. 1995;11:1675–83.PubMed
26.
Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA. Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther. 2009;7:268–76.PubMedPubMedCentral
27.
Kastan MB, Zhan Q, el Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–97.CrossRefPubMed
28.
Takekawa M, Saito H. A family of stress-inducible Gadd45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95:521–30.CrossRefPubMed
29.
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, et al. Gadd45 induction of a G2/m cell cycle checkpoint. Proc Natl Acad Sci U S A. 1999;96:3706–11.CrossRefPubMedPubMedCentral
30.
Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-m transition genes. Cancer Res. 2014;74:1452–62.CrossRefPubMed
31.
Sun Y, Tang S, Xiao X. The effect of Gadd45a on furazolidone-induced S-phase cell-cycle arrest in human hepatoma G2 cells. J Biochem Mol Toxicol. 2015. doi:10.​1002/​jbt.​21719.
32.
Fornace Jr AJ, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol. 1989;9:4196–203.CrossRefPubMedPubMedCentral
33.
Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF. Gadd45 proteins: central players in tumorigenesis. Curr Mol Med. 2012;12:634–51.CrossRefPubMedPubMedCentral
34.
Sun L, Gong R, Wan B, Huang X, Wu C, Zhang X, et al. Gadd45gamma, down-regulated in 65% hepatocellular carcinoma (HCC) from 23 Chinese patients, inhibits cell growth and induces cell cycle G2/m arrest for hepatoma Hep-G2 cell lines. Mol Biol Rep. 2003;30:249–53.CrossRefPubMed
35.
Zhang L, Yang Z, Ma A, Qu Y, Xia S, Xu D, et al. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma. Hepatology. 2014;59:178–89.CrossRefPubMed
36.
Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 2001;8:817–28.CrossRefPubMed
37.
Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A. 2002;99:207–12.CrossRefPubMed
38.
Lane MD, Tang QQ, Jiang MS. Role of the CCAAT enhancer binding proteins (C/EBPS) in adipocyte differentiation. Biochem Biophys Res Commun. 1999;266:677–83.CrossRefPubMed
39.
Tang QQ, Lane MD. Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes Dev. 1999;13:2231–41.CrossRefPubMedPubMedCentral
40.
Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611–9.CrossRefPubMed
Metadata
Title
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis
Authors
Lijuan Chen
Hua Tian
Meng Li
Chao Ge
Fangyu Zhao
Lixing Zhang
Hong Li
Junxi Liu
Tingpu Wang
Ming Yao
Jinjun Li
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4362-6

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

Nuclear PARP1 expression and its prognostic significance in breast cancer patients

Erratum

Erratum to: UBE2S is associated with malignant characteristics of breast cancer cells

Erratum

Erratum to: Increased expression of MyD88 and association with paclitaxel resistance in breast cancer

Original Article

Nutrient deprivation-related OXPHOS/glycolysis interconversion via HIF-1α/C-MYC pathway in U251 cells

Original Article

Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis

Original Article

Prognostic significance of GPC5 expression in patients with prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits